Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1636 1637 1653 1663 1699 4100
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18555503 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | Non-Final OA | The Regents of the University of California |
| 17924304 | SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19 | Non-Final OA | The Regents of the University of California |
| 18064738 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | Non-Final OA | President and Fellows of Harvard College |
| 19345390 | ENCODING METHODS FOR MULTIPLEXED DETECTION OF TARGETS IN CELLS | Final Rejection | Singular Genomics Systems, Inc. |
| 16321777 | EXPRESSION OF PTEN-LONG WITH ONCOLYTIC VIRUSES | Final Rejection | OHIO STATE INNOVATION FOUNDATION |
| 17814384 | VIRAL VECTORS FOR ENHANCED ULTRASOUND-MEDIATED DELIVERY TO THE BRAIN | Non-Final OA | California Institute of Technology |
| 17929013 | METHODS FOR RAPID CLONING AND EXPRESSION OF HLA CLASS I CELLS | Final Rejection | Board of Regents, The University of Texas System |
| 18569059 | TYPE V RNA PROGRAMMABLE ENDONUCLEASE SYSTEMS | Non-Final OA | Bayer Aktiengesellschaft |
| 17932239 | SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES | Final Rejection | CITY OF HOPE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy